WO2024246852 - METHOD OF TREATING FIBROTIC DISEASES USING PROTEIN KINASE INHIBITOR
National phase entry is expected:
Publication Number
WO/2024/246852
Publication Date
05.12.2024
International Application No.
PCT/IB2024/055335
International Filing Date
31.05.2024
Title **
[English]
METHOD OF TREATING FIBROTIC DISEASES USING PROTEIN KINASE INHIBITOR
[French]
MÉTHODE DE TRAITEMENT DE MALADIES FIBROTIQUES À L'AIDE D'UN INHIBITEUR DE PROTÉINE KINASE
Applicants **
AURIGENE ONCOLOGY LIMITED
39/40 (P), KIADB Industrial Area, Electronic City Phase II
Bangalore 560100, IN
Inventors
RAMACHANDRA, Muralidhara
V173, Adarsh Palm Retreat, Outer Ring
Road, Bellandur Post
Bangalore 560103, IN
CHELUR, Shekar S
BENAKA, # 181, Royal Lakefront Residency Phase 3, JP Nagar 9th Phase 7th Block
Bengaluru 560108, IN
THIYAGARAJAN, Saravanan
Flat 205, C Block, Vandana Earls Court, VGP Layout (Near Smash and Sprint), Kudlu
Bangalore 560068, IN
DAS, Payel
Block C, Flat 1408, Purva Westend, Kudlu Gate, GB Palya
Bengaluru 560068, IN
Priority Data
202341037798
01.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2523 | |
| EPO | Filing, Examination | 24769 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 10480 |
Total: 38937 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to a method of treating or delaying the progression of fibrosis in a subject comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a method for administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to a lung.[French]
La présente divulgation concerne une méthode de traitement ou de ralentissement de la progression de la fibrose chez un sujet, comprenant l'administration du composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente divulgation concerne également une méthode d'administration du composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci à un poumon.